Asymptomatic hyperuricemia
Conditions
Interventions
Control group:Only have low purine diet
Experimental group:take febuxostat orally
Sponsors
The Affiliated Huai'an 1st People's Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years old, male or female; 2. blood uric acid>480umol/l (8mg/dl); 3. Patients who do not use drugs that can reduce uric acid metabolism or excretion 2 weeks before participating in this study; 4. Carotid artery ultrasonography shows carotid artery intima-media thickness=1.2mm; 5. Volunteer and sign informed consent form.
Exclusion criteria
Exclusion criteria: 1. There was a history of gout in more than 1 joint; 2. Secondary hyperuricemia,such as malignant disease,leading a large increase in uric acid salts; 3. There was a history of Febuxostat allergy; 4. Patients who were treated or will treat with systemic hormone or immunosuppressive therapy 6 months before participating in this study; 5. Patients who use drugs that can reduce uric acid metabolism or excretion 2 weeks before participating in this study; 6. Patients who are using drugs that can reduce uric acid metabolism or excretion, and cannot or cannot be stopped following drugs, azathioprine, 6-mercaptopurine, aspirin(more than 325 mg/d), other salicylic acid, thiazide diuretic. 7. Abnormal liver function,ALT or AST was 1.5 times higher than normal value; 8. The white blood cell count is less than 4.0×10^9/Lthe platelet count is less than 100×10^9/L,Hemoglobin concentrations are below 90g/L; 9. BMI is equal or greater than 30kg/m2; 10. Uncontrolled high blood pressure(Blood pressure=160/100mmHg), Uncontrolled diabetes mellitus(FBG=8.5mmol/l); 11. Patients diagnosed with myocardial infarction,angina,coronary stenting or bypass surgery,heart failure, brain infarction, cerebral hemorrhage, subarachnoid hemorrhage,transient ischemic attack within 3 months; 12. Malignant tumor patient. 13. Alcoholics; 14. Woman during pregnancy or lactation,unwilling to take effective contraception during childbearing years, plan to conceive during the trial,the results of urine HCG examination before the test were positive; 15. Be tested for other drug clinical trials 3 months before screening; 16. Other factors researcher considers not suitable for inclusion.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| blood pressure;blood glucose;insulin;carotid artery intima-media thickness;height;weight;oxidative stress markers; | — |
Primary
| Measure | Time frame |
|---|---|
| blood uric acid;blood lipid; | — |
Countries
China
Contacts
Public ContactLi Mao
The Affiliated Huai'an 1st People's Hospital of Nanjing Medical University
Outcome results
None listed